Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 12;8(Suppl 9):e013534.
doi: 10.1136/bmjgh-2023-013534.

Research opportunities for the primordial prevention of rheumatic fever and rheumatic heart disease-streptococcal vaccine development: a national heart, lung and blood institute workshop report

Alma Fulurija  1   2 , Madeleine W Cunningham  3 , Natalia Korotkova  4 , Mary Y Masterson  5 , Geetha P Bansal  6 , Michael G Baker  7 , Jeffrey W Cannon  2   8 , Jonathan R Carapetis  9   2   10 , Andrew C Steer  11
Affiliations
Review

Research opportunities for the primordial prevention of rheumatic fever and rheumatic heart disease-streptococcal vaccine development: a national heart, lung and blood institute workshop report

Alma Fulurija et al. BMJ Glob Health. .

Abstract

Streptococcus pyogenes, also known as group A streptococcus (StrepA), is a bacterium that causes a range of human diseases, including pharyngitis, impetigo, invasive infections, and post-infection immune sequelae such as rheumatic fever and rheumatic heart disease. StrepA infections cause some of the highest burden of disease and death in mostly young populations in low-resource settings. Despite decades of effort, there is still no licensed StrepA vaccine, which if developed, could be a cost-effective way to reduce the incidence of disease. Several challenges, including technical and regulatory hurdles, safety concerns and a lack of investment have hindered StrepA vaccine development. Barriers to developing a StrepA vaccine must be overcome in the future by prioritising key areas of research including greater understanding of StrepA immunobiology and autoimmunity risk, better animal models that mimic human disease, expanding the StrepA vaccine pipeline and supporting vaccine clinical trials. The development of a StrepA vaccine is a complex and challenging process that requires significant resources and investment. Given the global burden of StrepA infections and the potential for a vaccine to save lives and livelihoods, StrepA vaccine development is an area of research that deserves considerable support. This report summarises the findings of the Primordial Prevention Working Group-VAX, which was convened in November 2021 by the National Heart, Lung, and Blood Institute. The focus of this report is to identify research gaps within the current StrepA vaccine landscape and find opportunities and develop priorities to promote the rapid and successful advancement of StrepA vaccines.

Keywords: Cardiovascular disease; Infections, diseases, disorders, injuries; Prevention strategies; Public Health; Review.

PubMed Disclaimer

Conflict of interest statement

Competing interests: MWC, JRC and ACS have received funding support from the National Institutes of Health. MWC received fees as a consultant for Vaxform Incorporated, Serum India Institute and Pfizer Incorporated. MWC is the Chief Scientific Officer and co-founder, with financial interest, in Moleculera Labs, a commercial laboratory for diagnostic testing of autoantibodies against the heart and brain.

Figures

Figure 1
Figure 1
Research priorities for surveillance sites.
See this image and copyright information in PMC

References

    1. Carapetis JR, Steer AC, Mulholland EK, et al. The global burden of group A streptococcal diseases. The Lancet Infectious Diseases 2005;5:685–94. 10.1016/S1473-3099(05)70267-X - DOI - PubMed
    1. Ralph AP, Carapetis JR. Group a streptococcal diseases and their global burden. Curr Top Microbiol Immunol 2013;368:1–27. 10.1007/82_2012_280 - DOI - PubMed
    1. Walker MJ, Barnett TC, McArthur JD, et al. Disease manifestations and pathogenic mechanisms of group A streptococcus. Clin Microbiol Rev 2014;27:264–301. 10.1128/CMR.00101-13 - DOI - PMC - PubMed
    1. Miller KM, Carapetis JR, Van Beneden CA, et al. The global burden of sore throat and group A streptococcus pharyngitis: a systematic review and meta-analysis. eClinicalMedicine 2022;48:101458. 10.1016/j.eclinm.2022.101458 - DOI - PMC - PubMed
    1. Craik N, Hla T, Cannon J, et al. Global disease burden of Streptococcus Pyogenes. In: Ferretti JJ, Stevens DL, Fischetti VA, eds. Streptococcus pyogenes: Basic Biology to Clinical Manifestations. 2nd edn. Oklahoma City (OK), 2022.

MeSH terms

Substances